Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;29(14):879-881.
doi: 10.1089/scd.2020.0095. Epub 2020 Jun 10.

Response to Lim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19"

Vikram Sengupta  1   2 , Sascha Sengupta  2   3 , Angel Lazo Jr  4 , Kevin C Hicok  5 , Timothy Moseley  5
Affiliations
Comment

Response to Lim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19"

Vikram Sengupta et al. Stem Cells Dev. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

T.M. and K.H. serve as chief science officer and director of research and development, respectively, at Direct Biologics LLC, Austin, TX, from which they receive their paychecks and have a vested financial interest in the success of ExoFlo as a therapy. All other authors declare no competing financial interests exist.

Figures

FIG. 1.
FIG. 1.
(A) Fluorescent image of ExoFlo™ that was triple stained with antibodies against tetraspanin proteins reported in the literature to be enriched in exosomes using the NanoView Biosciences NanoView system. Red fluorescence, CD63; blue fluorescence, CD9; green fluorescence, CD81. (B) Semiquantification analysis of ExoFlo nanoparticles captured on different Nanoview antibody capture arrays. Data demonstrate an exosome population highly enriched for CD63 expression is the dominant EV population. EV, extracellular vesicle.
See this image and copyright information in PMC

Comment on

References

    1. Sengupta V, Sengupta S, Lazo Jr A, Woods P, Nolan A and Bremer N (2020). Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 29:747–754 - PMC - PubMed
    1. Lim SK, Giebel B, Weiss DJ, Witwer KW and Rohde E (2020). Re: “Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19” by Sengupta et al. Stem Cells Dev 29:877–878 - PMC - PubMed
    1. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, et al. (2015). Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3:24–32 - PMC - PubMed

LinkOut - more resources